Navigation Links
Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Date:3/19/2008

SCHAUMBURG, Ill., March 19 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous (I.V.) administration used to treat bacterial infections. Sagent's ciprofloxacin injection will be available immediately in 200mg and 400mg premix bags. According to IMS data, sales of injectable ciprofloxacin in the United States in 2006 were approximately $60 million.

"We are poised to be one of the first companies to make the I.V. form of this important antibiotic widely available to patients in the U.S.," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The launch of our ciprofloxacin -- in ready-to-use, customer friendly, barcoded I.V. bags -- simultaneous with the expiry of the innovator's patent exclusivity further demonstrates Sagent's capabilities and expertise in injectable pharmaceutical products and our seasoned management team's commitment to the needs of patients and customers."

Ciprofloxacin is the third product introduced from Sagent's pipeline of more than 200 products since the launch of the company's first product, adenosine injection, USP, in December 2007. Earlier this month, the company launched another antibiotic, cefazolin for injection, USP, which is available in 1g single dose vials and 10g pharmacy bulk package vials.

About Ciprofloxacin

Ciprofloxacin injection, USP, is a synthetic broad spectrum antimicrobial agent for intravenous administration used to treat a variety of infections and is the generic equivalent of Bayer Pharmaceuticals' CIPRO(R) I.V. Ciprofloxacin belongs to the fluoroquinolone family of drugs. Ciprofloxacin injection, USP, is indicated for infections of the urinary tract, skin and skin structure, bones and joints, as well as nosocomial pneumonia, acute sinusitis, chronic bacterial prostatitits, lower respiratory infections and complicated intra-abdominal infections. In addition, ciprofloxacin can be effective in reducing the incidence or progression of inhalational anthrax following exposure to the bacteria. The most common adverse effects may include nausea, vomiting, dizziness or drowsiness, blurred vision, insomnia, joint stiffness or muscle pain or photosensitivity. Less common adverse effects include seizure, psychological episodes, jaundice, diarrhea, numbness or tingling, or chest pain or palpitations. Rarely, ciprofloxacin can cause joint damage, including tendon rupture.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of

pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: